Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in alzheimer disease

Robert A. Rosenheck, Douglas L. Leslie, Jody L. Sindelar, Edward A. Miller, Peter N. Tariot, Karen S. Dagerman, Sonia M. Davis, Barry D. Lebowitz, Peter Rabins, John K. Hsiao, Jeffery A. Lieberman, Lon S. Schneider

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in alzheimer disease'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences

Medicine and Dentistry